# Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

> **NCT03600805** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 83 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Sarilumab SAR153191
- **DRUG:** Sarilumab matching placebo
- **DRUG:** Prednisone
- **DRUG:** Prednisone matching placebo

## Key facts

- **NCT ID:** NCT03600805
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-20
- **Primary completion:** 2020-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Protracted recruitment timeline exacerbated by COVID-19 pandemic
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600805, "Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03600805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*